ArticleReproductive sciences (Thousand Oaks, Calif.)2026
The Solute Carrier (SLC) Transporter Superfamily as Therapeutic Targets for the Treatment of Ovarian Serous Cystadenocarcinoma.
Article in Reproductive sciences (Thousand Oaks, Calif.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Ovarian serous cystadenocarcinoma (OV) is one of the deadliest gynecologic cancers, primarily due to late-stage diagnosis and limited treatment options. Precision oncology seeks to personalize cancer treatment based on individual genetic profiles and tumor characteristics. The solute carrier (SLC) transporter superfamily, consisting of over 400 proteins across 65 families, is vital for numerous cellular functions and presents promising therapeutic targets. This study provides a comprehensive analysis of SLC transporters by integrating mRNA and protein expression from The Cancer Genome Atlas (TCGA) and The Human Protein Atlas (HPA). Gene Set Enrichment Analysis (GSEA) was performed to evaluate the involvement of SLC transporters in diverse oncogenic pathways. Significant upregulation of SLC transporters was observed in tumor tissues compared to normal tissues, notably for SLC57A5, SLC16A3, SLC20A2, and SLC34A2. This upregulation was associated with poorer overall survival (OS) and disease-specific survival (DSS). Gene Set Enrichment Analysis (GSEA) indicated that these transporters are significantly involved in crucial oncogenic pathways, including the epithelial-mesenchymal transition (EMT), angiogenesis, and Hedgehog signaling pathways. This study identifies SLC transporters as potential biomarkers and therapeutic targets in OV. By targeting these transporters with small molecule inhibitors, it may be possible to disrupt essential metabolic pathways in cancer cells, thereby enhancing treatment efficacy and improving patient outcomes. This research establishes a foundation for the development of SLC-targeted therapies in precision oncology, aiming to improve survival rates for patients with OV.
Indexed as
Identifiers
41530649What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.